Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th

Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017.  At 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.  

After releasing first quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.

Conference Call InformationWhen: Monday, May 8, 2017 at 4:30 p.m. EDTDial-in: [phone] (toll free) or [phone] (International) Conference ID: 8313325Webcast:  http://investors.coherus.comPlease join the conference call at least 10 minutes early to register.  The webcast will be archived on the Coherus website.

About Coherus BioSciences, Inc.Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.          

CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[e-mail]
[phone]